IL-6/STAT3 and PIK3CA inhibition did not reverse platinum chemoresistance in ovarian cancer and IL-6 levels cannot be considered as a marker of sensitivity to platinum-based chemotherapy. Here, PIK3CA is linked to ovarian carcinoma.